Pelletier. G G; Petitclerc. D D; Lapierre. H H; Bernier-Cardou. M M; Morisset. J J; Gaudreau. P P; C...
In a study with dairy cows, giving synthetic human growth hormone‑releasing factor (either the full 44‑amino‑acid version or a shorter 29‑amino‑acid fragment) boosted milk production by about 15‑19% without changing how much the cows ate, and it made the feed they did eat work more efficiently.
Csernus. V J VJ; Schally. A V AV; Kiaris. H H; Armatis. P P
The study shows that chemicals that block the hormone that normally tells the pituitary to release growth hormone (called GHRH antagonists) can slow the growth of several cancer cell lines by cutting down the amount of a growth factor called IGF‑II that many tumors make themselves. This effect is separate from the usual growth‑hormone/IGF‑I pathway and works by interfering with the tumor’s own IGF‑II signaling loop.
Researchers measured how a radioactive version of human growth hormone‑releasing factor (GRF, also called sermorelin) sticks to rat pituitary tissue. They found two kinds of binding spots: one that grabs the peptide tightly but in small numbers, and another that holds it more loosely but in larger numbers. The test works best with a modest amount of magnesium, and the binding can be stopped with EDTA to keep the peptide stable.
In pregnant rats, blood levels of growth hormone (GH) rise a lot during the later stages of pregnancy, especially on day 20, mainly because the baseline GH goes up and the bursts of GH become larger. Giving a human GH‑releasing factor (GRF) analogue still boosts GH, but if the pituitary gland is removed, GH disappears, showing the pituitary is the source.
Valtorta. A A; Moretta. A A; Maccario. R R; Bozzola. M M; Severi. F F
In a lab test, tiny amounts of the short form of human growth‑hormone‑releasing hormone (GHRH 1‑29) helped immune cells multiply when they were stimulated, but larger amounts actually slowed their activity and reduced a key immune signal (IL‑2). The longer form (GHRH 1‑44) didn’t change anything, and the hormone wasn’t toxic to the cells.
Hart. I C IC; Chadwick. P M PM; Coert. A A; James. S S; Simmonds. A D AD
In sheep, different forms of growth‑hormone‑releasing factor (including ones similar to sermorelin) all boosted GH levels, and the boost was actually bigger when the animals were on a restricted diet. The type of GRF mattered less than whether the animal was eating a lot or a little.
Lance. V A VA; Murphy. W A WA; Sueiras-Diaz. J J; Coy. D H DH
Scientists made several modified versions of the growth‑hormone‑releasing peptide (like sermorelin) and tested them in rats and pigs. One version, with a D‑alanine at position 2, was about 50 times stronger at making the body release growth hormone than the regular peptide. The other tweaks were also stronger than the original, but not as dramatic.
Costoya. Joel J; Gaumond. Simonetta I SI; Chale. Ravinder S RS; Schally. Andrew V AV; Jimenez. Joaqu...
The study looks at a new drug called MIA-602 that blocks a hormone signal (GHRH) and shows it can kill leukemia cells in lab tests, even those that resist standard chemo, and works better when combined with chemo. However, this is early‑stage cancer research, not a health‑boosting supplement, and it isn’t ready for personal use.
Scientists found that drugs that block the hormone that normally tells the body to release growth hormone can make lung cancer cells more vulnerable to radiation in lab dishes, but this research used special lab compounds, not the growth‑hormone‑releasing peptide sermorelin, and it’s far from any real‑world self‑experiment or treatment plan.
Telegdy. Gyula G; Tanaka. Masaru M; Schally. Andrew V AV
In mice, a brain‑injected GH‑releasing hormone blocker called MZ‑4‑71 helped them remember a task better, stopped memory loss caused by a beta‑amyloid peptide, and showed mild anti‑depression and anti‑anxiety effects, without changing general activity. However, the study used direct brain injections in animals, so it doesn’t give clear guidance for people to use this or related peptides like sermorelin in real life.
Qin. Yong Jie YJ; Chan. Sun On SO; Chong. Kelvin Kam Lung KK; Li. Benjamin Fuk Loi BF; Ng. Tsz Kin T...
A study in rats showed that blocking the receptor for growth‑hormone‑releasing hormone (GHRH) reduced eye inflammation caused by a bacterial toxin, lowering hormone levels and immune‑cell infiltration in the eye.
Hohla. Florian F; Buchholz. Stefan S; Schally. Andrew V AV; Seitz. Stefan S; Rick. Ferenc G FG; Szal...
The study shows that a synthetic molecule that blocks growth‑hormone‑releasing hormone (GHRH) can damage DNA in colon‑cancer cells, trigger cell‑death pathways, and shrink tumors in mice, but it doesn’t tell you how to use it for health‑boosting or longevity in normal people.
The study shows that the receptor for growth‑hormone‑releasing hormone (GHRH‑R) helps drive eye inflammation by activating a JAK2‑STAT3 signaling chain, and that blocking this receptor or using a JAK inhibitor can calm the inflammation in animal and cell models.
Rick. Ferenc G FG; Szalontay. Luca L; Schally. Andrew V AV; Block. Norman L NL; Nadji. Mehrdad M; Sz...
In rats with hormone‑induced enlarged prostates, giving a drug that blocks growth‑hormone‑releasing hormone (GHRH) together with a drug that blocks luteinizing‑hormone‑releasing hormone (LHRH) cut prostate size by about 30% and lowered several prostate‑related blood markers.
Rick. Ferenc G FG; Schally. Andrew V AV; Block. Norman L NL; Nadji. Mehrdad M; Szepeshazi. Karoly K;...
In a rat study, drugs that block the hormone GHRH shrank enlarged prostates by about 18‑21% after six weeks and lowered inflammation markers, but the work used GHRH antagonists, not the growth‑stimulating peptide sermorelin, and was done only in animals.
Stangelberger. Anton A; Schally. Andrew V AV; Rick. Ferenc G FG; Varga. Jozsef L JL; Baker. Benjamin...
In mouse studies, a drug that blocks the growth‑hormone‑releasing hormone (GHRH) slowed the growth of prostate cancer tumors and changed key cancer‑related proteins, especially p53. Adding another hormone blocker (Cetrorelix) made the effect stronger. The work doesn’t involve sermorelin (a GHRH‑activating peptide) and offers no direct guidance for human use.
Siejka. Agnieszka A; Barabutis. Nektarios N; Schally. Andrew V AV
A lab study found that a synthetic growth‑hormone‑releasing‑hormone blocker (MZ‑5‑156) can slow the growth of lung cancer cells by turning on a cellular energy sensor called AMPK and shutting down growth signals, but this was only shown in cancer cells in a dish, not in people.
Siejka. Agnieszka A; Barabutis. Nektarios N; Schally. Andrew V AV
The study found that a lab-made GHRH blocker (MZ-5-156) can shut down a signaling protein (FAK) and lower levels of molecules that help lung cancer cells grow new blood vessels and invade tissue, but this was only shown in cell dishes and uses a compound not available to the public.
Rick. Ferenc G FG; Seitz. Stephan S; Schally. Andrew V AV; Szalontay. Luca L; Krishan. Awtar A; Datz...
A study found that a growth‑hormone‑releasing‑hormone blocker called JMR‑132 can pause colon‑cancer cells in the DNA‑making phase and make chemotherapy work better in lab dishes and mice, shrinking tumors by up to half. This isn’t about sermorelin (a hormone‑boosting peptide) and it’s only in animals, so it doesn’t give a usable plan for everyday health hacking.
Muñoz-Moreno. Laura L; Arenas. M Isabel MI; Schally. Andrew V AV; Fernández-Martínez....
This study tested two chemicals that block the hormone that normally tells the body to release growth hormone. In mice with aggressive prostate cancer, these blockers slowed tumor growth and reduced markers linked to blood‑vessel formation and spread. The work is about cancer treatment, not about using growth‑hormone‑releasing peptides like sermorelin for health‑boosting purposes.